Fri, Aug 22, 2014, 10:40 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • dinepat203 dinepat203 Oct 22, 2012 12:18 PM Flag

    ISIS going to be like GENZYME shares $74 ....Keep holding ISIS..A GENETIC DISORDER SPECIALIST

    Sanofi-Aventis SA agreed to buy Genzyme Corp., ending a nine-month pursuit of the U.S. biotechnology company with a sweetened offer of at least $20.1 billion that gives France’s biggest drugmaker treatments for rare diseases.
    Genzyme’s stockholders will get $74 a share in cash, Paris- based Sanofi said today in a statement. They also will receive so-called contingent value rights that entitle them to payments of as much as $14 a share depending on the performance of Genzyme’s experimental multiple-sclerosis drug Lemtrada and production levels of two other products, the company said.

    Acquiring Genzyme, the world’s largest maker of medicines for rare genetic disorders, will help Chief Executive Officer Chris Viehbacher offset revenue losses as some of Sanofi’s biggest-selling products face competition from generic versions. Sanofi gains treatments for Fabry, Gaucher and Pompe diseases.

    Sentiment: Strong Buy

 
ISIS
34.33+0.16(+0.47%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT
Salesforce.com, Inc
NYSEFri, Aug 22, 2014 4:00 PM EDT